Polypharmacy, Adverse Drug Reactions and Drug-Drug Interactions in COVID-19-Aging Patients

Considerations on the Clinical Picture

Autores

  • Marileia Andrade Unimontes
  • José Henrique Pereira Pinto Faculdade de Medicina de Itajubá

DOI:

https://doi.org/10.46551/ruc.v22n2a02

Palavras-chave:

COVID-19;, Elderly;, Polypharmacy;, Adverse Drug Reactions;, Drug Interactions

Resumo

Since the beginning of the Coronavirus Disease 2019 (COVID-19) pandemic, the most severe symptoms have occurred in elderly patients with comorbidities, with a higher risk of complications. Prescribed drugs, which are already part of geriatric care, associated with the experimental therapeutic drugs of COVID-19, may increase the risk of undesirable occurrences, due to the practice of polypharmacy, with the possibility of emergence of inappropriate adverse events and drug interactions. This can increase the risk of worsening the clinical picture, impairment of the general condition, intensification of inflammation and associated unfavorable conditions, incurring the highest probability of mortality.

Downloads

Não há dados estatísticos.

Referências

ZHOU Fei; YU Ting, DU Ronghui, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, v. 28, 395(10229), p.1054-1062, 2020. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Erratum in: Lancet. 2020 Mar 28;395(10229):1038.

OLIVEIRA Marcus Vinícius Palmeira; BUARQUE David Costa. Polypharmacy and the use of potentially inappropriate medications among aged in patients. Geriatrics, Gerontology and Aging, v.12, n.1, p.38-44, 2018.

BENNETT Alexander; GNJIDIC Danijela; GILLETT Mark, et al. Prevalence and impact of fall-risk-increasing drugs, polypharmacy, and drug-drug interactions in robust versus frail hospitalised falls patients: a prospective cohort study. Drugs Aging, v.31, n.3, p.225-232, 2014.

HU Biying; HUANG Shaoying; YIN Lianghong. The cytokine storm and COVID-19. Journal of Medical Virology, v.27, 10.1002/jmv.26232, 2020.

ISIDORO-GARCIA Maria; SANCHEZ-MARTIN Almudena, GARCIA-BERROCAL Belén, et al. Primun non nocere, polypharmacy and pharmacogenetics. Pharmacogenomics, v16, n.17, p.1903–1905, 2015.

McCREARY Erin K, POGUE Jason M. Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. Open Forum Infectious Diseases, v.7, n.4, ofaa105, 2020.

GELERIS Joshua; SUN Yifei; PLATT Jonathan, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. The New England Journal of Medicine, v.382, n.18, p.2411-2418, 2020.

LEMAITRE Caroline Solas Florian; GRÉGOIRE Matthieu; LAGARCE Laurence, et al. Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments. Fundamental & Clinical Pharmacology, v.34, n.5, p.530–547, 2020.

ROSS Sydney B; WILSON Marnie Goodwin, PAPILLON-FERLAND Louise, et al. COVID-SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults. Journal of the American Geriatrics Society, v.68, n.8, p.1636–1646, 2020.

LANE Jennifer CE; WEAVER James; KOSTKA Kristin, et al. Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid widespread use for COVID-19: a multinational, network cohort and self- controlled case series study. MedRxiv preprint, May 31, p:1-29, 2020.

Downloads

Publicado

2020-12-31

Como Citar

ANDRADE, M.; PINTO , J. H. P. . Polypharmacy, Adverse Drug Reactions and Drug-Drug Interactions in COVID-19-Aging Patients: Considerations on the Clinical Picture. Revista Unimontes Científica, v. 22, n. 2, p. 1-4, 31 dez. 2020.

Edição

Seção

Cartas ao editor - Dossiê Temático Covid